(QDEL) Quidel - Ratings and Ratios
Clinical Chemistry, Immunoassay, Transfusion Typing, Rapid POC, PCR Testing
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 53.1% |
| Value at Risk 5%th | 76.4% |
| Relative Tail Risk | -12.55% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.33 |
| Alpha | -61.77 |
| CAGR/Max DD | -0.38 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.496 |
| Beta | 1.605 |
| Beta Downside | 1.716 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.05% |
| Mean DD | 43.98% |
| Median DD | 53.72% |
Description: QDEL Quidel November 12, 2025
QuidelOrtho Corporation (NASDAQ: QDEL) develops and markets a broad portfolio of diagnostic testing solutions across four business units: Labs, Transfusion Medicine, Point-of-Care (POC), and Molecular Diagnostics.
The Labs unit supplies clinical chemistry and immunoassay instruments and reagents for measuring chemicals, proteins, and disease markers in bodily fluids; the Transfusion Medicine unit provides blood-typing and donor-screening systems to ensure safe transfusions; the POC unit delivers rapid, near-patient testing platforms for settings ranging from urgent-care clinics to retail pharmacies; and the Molecular Diagnostics unit offers PCR-based thermocyclers and sample-to-result platforms for syndromic infectious-disease testing.
QuidelOrtho reaches end users through a direct sales force and a global distributor network that serves hospitals, reference labs, physician offices, blood banks, and over-the-counter consumers across North America, Europe, the Middle East, Africa, China, and other international markets.
Key recent metrics (Q3 2024) include $1.22 billion in total revenue-a 12 % year-over-year increase driven largely by sustained demand for rapid COVID-19 antigen tests and expanded adoption of molecular panels for respiratory infections. The company’s POC segment now accounts for roughly 38 % of revenue, reflecting a broader industry shift toward decentralized testing as healthcare providers seek to reduce turnaround times and lower costs. Additionally, QuidelOrtho’s operating margin improved to 15 % after cost-containment initiatives, positioning it favorably against the average 13 % margin for the Health Care Supplies sub-industry.
For a deeper, data-driven analysis of QuidelOrtho’s valuation and risk profile, you may find the research tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-1.18b TTM) > 0 and > 6% of Revenue (6% = 162.9m TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA 0.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 22.05% (prev 13.67%; Δ 8.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 37.0m > Net Income -1.18b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (68.0m) change vs 12m ago 1.04% (target <= -2.0% for YES) |
| Gross Margin 57.07% (prev 47.62%; Δ 9.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 43.53% (prev 41.43%; Δ 2.10pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.34 (EBITDA TTM -518.2m / Interest Expense TTM 179.2m) >= 6 (WARN >= 3) |
Altman Z'' -1.09
| (A) 0.11 = (Total Current Assets 1.37b - Total Current Liabilities 767.9m) / Total Assets 5.68b |
| (B) -0.15 = Retained Earnings (Balance) -865.3m / Total Assets 5.68b |
| (C) -0.15 = EBIT TTM -957.0m / Avg Total Assets 6.24b |
| (D) -0.24 = Book Value of Equity -884.9m / Total Liabilities 3.64b |
| Total Rating: -1.09 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 24.00
| 1. Piotroski 2.50pt |
| 2. FCF Yield -0.90% |
| 3. FCF Margin -1.58% |
| 4. Debt/Equity 1.40 |
| 5. Debt/Ebitda -5.30 |
| 6. ROIC - WACC (= -23.45)% |
| 7. RoE -43.64% |
| 8. Rev. Trend -36.02% |
| 9. EPS Trend -77.17% |
What is the price of QDEL shares?
Over the past week, the price has changed by -1.00%, over one month by +7.56%, over three months by +4.19% and over the past year by -35.98%.
Is QDEL a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 2
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the QDEL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.7 | 31.8% |
| Analysts Target Price | 37.7 | 31.8% |
| ValueRay Target Price | 20.5 | -28.2% |
QDEL Fundamental Data Overview December 19, 2025
P/E Forward = 10.917
P/S = 0.7355
P/B = 0.9641
P/EG = 7.19
Beta = 0.584
Revenue TTM = 2.72b USD
EBIT TTM = -957.0m USD
EBITDA TTM = -518.2m USD
Long Term Debt = 2.50b USD (from longTermDebt, last quarter)
Short Term Debt = 191.8m USD (from shortTermDebt, last quarter)
Debt = 2.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.75b USD (from netDebt column, last quarter)
Enterprise Value = 4.74b USD (2.00b + Debt 2.84b - CCE 98.1m)
Interest Coverage Ratio = -5.34 (Ebit TTM -957.0m / Interest Expense TTM 179.2m)
FCF Yield = -0.90% (FCF TTM -42.8m / Enterprise Value 4.74b)
FCF Margin = -1.58% (FCF TTM -42.8m / Revenue TTM 2.72b)
Net Margin = -43.43% (Net Income TTM -1.18b / Revenue TTM 2.72b)
Gross Margin = 57.07% ((Revenue TTM 2.72b - Cost of Revenue TTM 1.17b) / Revenue TTM)
Gross Margin QoQ = 93.18% (prev 37.12%)
Tobins Q-Ratio = 0.84 (Enterprise Value 4.74b / Total Assets 5.68b)
Interest Expense / Debt = 1.62% (Interest Expense 46.1m / Debt 2.84b)
Taxrate = 3.16% (-23.9m / -756.9m)
NOPAT = -926.8m (EBIT -957.0m * (1 - 3.16%)) [loss with tax shield]
Current Ratio = 1.78 (Total Current Assets 1.37b / Total Current Liabilities 767.9m)
Debt / Equity = 1.40 (Debt 2.84b / totalStockholderEquity, last quarter 2.04b)
Debt / EBITDA = -5.30 (negative EBITDA) (Net Debt 2.75b / EBITDA -518.2m)
Debt / FCF = -64.15 (negative FCF - burning cash) (Net Debt 2.75b / FCF TTM -42.8m)
Total Stockholder Equity = 2.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -20.78% (Net Income -1.18b / Total Assets 5.68b)
RoE = -43.64% (Net Income TTM -1.18b / Total Stockholder Equity 2.70b)
RoCE = -18.41% (EBIT -957.0m / Capital Employed (Equity 2.70b + L.T.Debt 2.50b))
RoIC = -17.60% (negative operating profit) (NOPAT -926.8m / Invested Capital 5.26b)
WACC = 5.84% (E(2.00b)/V(4.84b) * Re(11.93%) + D(2.84b)/V(4.84b) * Rd(1.62%) * (1-Tc(0.03)))
Discount Rate = 11.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.52%
Fair Price DCF = unknown (Cash Flow -42.8m)
EPS Correlation: -77.17 | EPS CAGR: -44.53% | SUE: 0.73 | # QB: 0
Revenue Correlation: -36.02 | Revenue CAGR: 2.55% | SUE: 0.95 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.82 | Chg30d=-0.039 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=2.53 | Chg30d=-0.457 | Revisions Net=-4 | Growth EPS=+21.8% | Growth Revenue=+2.3%
Additional Sources for QDEL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle